, due to loss in operation leading to decrease of shareholders’ equity more than interest-bearing debt recognition. Consolidated 2019 2018 Current Ratio (Times) 0.75 0.75 Interest-bearing Debt to Equity
the end of last year, due to loss in operation leading to decrease of shareholders’ equity more than interest-bearing debt recognition. Consolidated 2019 2018 Current Ratio (Times) 0.75 0.75 Interest
were executed on July 20, 2018 for the abovementioned ETB. Consequently, as a result of the abovementioned ETB, the company’ s consolidated financial statement as ended September 30, 2018 then recorded
follows: Baht’000 Consolidated F/S ∆% Separate F/S ∆% 2019 2018 2019 2018 Revenues from Sales and Services 1,921,477 2,060,114 -7% 1,518,926 1,640,996 -7% Other income 72,604 338,396 -79% 52,158 25,568 104
10.31425 billion THB, increasing 10.46% and 24.04% from 2018 respectively. The financial liquidity has efficiently been managed, therefore, the interest bearing debt to equity ratio and the debt to equity
“Company”) submitted its separate financial statement and its consolidated financial statement for the first quarter of 2020 ended on 31 March 2020 which were reviewed by the auditor. The Company hereby
Periods Ended 30 June, 2020 Page 6 2. Operation performance according to consolidated financial statement Unit : Million baht 2020 2019 2020 2019 Total revenues (excluding fuel costs) 3,695.63 4,387.88
, Suriyawong, Bangrak, Bangkok 10500, Thailand. Tel. 02-634-0225 Fax 02-634-0135 www.interpharma.co.th Consolidated For the Year Ended December 31 2019 2018 MB % MB % Total revenues 375.89 100.00 317.58 100.00
relation to import duty assessment. งบกาํไรขาดทุนเบ็ดเสร็จ Consolidated For the Year Ended December 31 2019 2018 MB % MB % Total revenues 375.89 100.00 317.58 100.00 Cost of sales (157.39) (41.87) (125.04
relation to import duty assessment. Consolidated For the Year Ended December 31 2019 2018 MB % MB % Total revenues 375.89 100.00 317.58 100.00 Cost of sales (157.39) (41.87) (125.04) (39.77) Selling expenses